Veracyte’s approach to interstitial lung disease (ILD) testing
EXCEPTIONAL TESTING FOR INTERSTITIAL LUNG DISEASE (ILD)
More confident diagnosis and prognosis with Envisia® Genomic Classifier
Veracyte’s Envisia Genomic Classifier is the first commercially available genomic test to help improve physicians’ ability to differentiate IPF from other ILDs. This can enable timely and appropriate treatment. The test combines powerful RNA sequencing and machine-learning technology to identify a genomic pattern of UIP in tissue from the lungs. UIP is critical to the diagnosis of IPF and is associated with a poor prognosis across multiple types of ILD.
Learn about Envisia Genomic Classifier for ILD
Cosgrove GP, et al. BMC Pulm Med. 2018.
Company estimates based on proportion of patients classified by various CT scan patterns (from Chung JH, et al. CHEST. 2015.).
The Envisia Genomic Classifier is available in the US as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA.
This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.